EMERGENT BIOSOLUTIONS INC. Restructuring and Related Cost, Cost Incurred to Date (Deprecated 2014-01-31)
EMERGENT BIOSOLUTIONS INC. (EBS) reported Restructuring and Related Cost, Cost Incurred to Date (Deprecated 2014-01-31) of $2.81 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostCostIncurredToDate · last filed 2014-03-10
- EMERGENT BIOSOLUTIONS INC. restructuring and related cost, cost incurred to date (deprecated 2014-01-31) for the quarter ending 2013-03-31 was $2.02M.
- EMERGENT BIOSOLUTIONS INC. restructuring and related cost, cost incurred to date (deprecated 2014-01-31) for fiscal 2013 was $2.81M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date (Deprecated 2014-01-31) 3 month | Restructuring and Related Cost, Cost Incurred to Date (Deprecated 2014-01-31) 12 month | Restructuring and Related Cost, Cost Incurred to Date (Deprecated 2014-01-31) 12 month as first filed |
|---|---|---|---|
| 2013-12-31 | $2.81M 10-K · filed 2014-03-10 | $2.79M 10-Q · filed 2013-05-03 | |
| 2013-03-31 | $2.02M 10-Q · filed 2013-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |